eligibility_summary
Eligibility: 1–18y DIPG post-RT, CNS reservoir catheter, PS ≥60, life expectancy ≥8 wks, organ function OK (AST/ALT <5×ULN, bili <3×, Cr <5×, SpO2 ≥90%), washouts: ≥7d chemo/biologic, ≤30d or 3 half-lives antibodies, ≥30d cellular, steroids ≤2.5 mg/m2/d, stable. Exclude: ≥grade 3 cardiac, immunodeficiency/BM failure, herniation risk, >grade 3 dysphagia, other active cancers, uncontrolled illness, pregnancy/breastfeeding, active HIV/HBV/HCV.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Autologous B7H3 (CD276)-specific CAR T-cell therapy (biologic, adoptive cell therapy) engineered via lentiviral transduction to include an IL‑7 receptor alpha signaling domain, delivered intraventricularly (locoregional) via CNS catheter after standard therapy. Mechanism: CAR binding to B7H3 on DIPG cells triggers T-cell activation and cytotoxic killing (TCR-independent CD3ζ signaling). The IL‑7Ra domain provides IL‑7/JAK‑STAT5 survival and proliferative signals to boost persistence, expansion, and reduce exhaustion within the CNS tumor microenvironment. Targets: B7H3-expressing DIPG tumor/tumor-associated cells, IL‑7/IL‑7R signaling in CAR T cells, T-cell perforin/granzyme effector pathways.